Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.
By I. Judson, J. Verweij, H. Gelderblom, J. Hartmann, P. Schöffski, J. Blay, J. Kerst, J. Šufliarsky, J. Whelan, P. Hohenberger and 9 more. The Lancet Oncology, 2014
1,048 citations recorded by the source corpus.
Subfields: Industrial and Manufacturing Engineering
View Paper: https://www.semanticscholar.org/paper/24136856e5dedd30a26ee5bbd82247767a16e2e9
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
- P. Casali
- J. Bovée
- J. Broto
- Robin L. Jones
- I. Judson
- A. Tos
- T. Gil
- A. Gronchi
Citations in the corpus
- Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2018, background): “However, a higher response rate can be expected, in particular, in a number of sensitive histological types, according to several, although not all, randomised clinical trials [26, 27].”